ABSTRACT ÖZET
Methods:
A total of 139 unselected Turkish patients with significant CAD (coronary lesion with 50-100% stenosis) and 120 control participants (coronary lesion with <30% stenosis) were genotyped for MIF rs755622 polymorphisms using hybridization probes in a Roche LightCycler 480 Real-Time Polymerase Chain Reaction 480 device. Blood samples were drawn before coronary angiography. Gensini and SYNTAX scores were used to determine the angiographic extent and severity of CAD.
Results: When the groups were stratified according to T2DM, polymorphism of MIF was not associated with T2DM in CAD patients (p>0.05). In the same subgroups, carriers of the MIF common allele in the control group demonstrated a protection against developing T2DM compared with noncarriers (p<0.05). In addition, MIF C allele carriage was associated with higher glycated hemoglobin (HbA1c) in the T2DM group (p=0.038).
Conclusion:
The MIF rs755622 polymorphism was associated with HbA1c. This result suggests that the MIF gene variant may contribute to CAD risk through diabetes in the Turkish population.
Amaç: Yapılan son çalışmalar, makrofaj migrasyon inhibitör faktörünün (MIF) ateroskleroz sırasında enflamatuvar sürece aracılık eden güçlü bir proenflamatuvar sitokin olduğunu gös-termektedir. Bu çalışmadaki amacımız, koroner arter hastalığı (KAH) olan ve KAH olmayan bireylerde MIF gen polimorfizmi ve tip 2 diyabetes mellitus (T2DM) arasındaki ilişkiyi araştır-maktır.
T he macrophage migration inhibitory factor (MIF)
is a pleiotropic cytokine of natural immunity. It represents an important component of antimicrobial and stress responses. [1] The MIF gene located at the 22q11.2 chromosomal region is a small gene consisting of three exons. [2] MIF gene is expressed in many cell types including monocytes, macrophages, vascular smooth muscle cells and cardiomyocytes. [3] [4] [5] Clinical studies have shown that MIF protein can be used as a biomarker for different diseases with an inflammatory component. [6] Recruiting cytokines and inflammatory cells, including monocytes and T lymphocytes to the vascular wound site through the action of chemokines, is the initial phase of atherosclerosis. [7] MIF protein, a strong proinflammatory cytokine, plays an important role in this process. [8] The relevant findings obtained indicate that MIF protein plays a role in the development of early atheromatous plaque and the progression of atherosclerotic lesions. [9] Thus, elevation of MIF protein levels may lead to the development of coronary artery disease (CAD). [8] A total of four polymorphisms, including single nucleotide polymorphisms (SNP) and -794CATT 5-8 microsatellite polymorphisms, have been reported in the human MIF gene as -173 (rs755622), +254 (rs2096525) and +656 (rs2070766). While rs2096525 and rs2070766 are found in introns, rs755622 and -794CATT [5] [6] [7] [8] are located in the promoter region. [10] The polymorphism at the G-173C point in the promoter region has been associated with an increase in MIF protein production in parallel with the increase in the transcription activity of the MIF gene. [10] In MONICA/KORA study, a relationship between MIF gene rs755622 and rs2070766 SNPs and corresponding haplotypes and CAD in women was reported. [11] In addition, it was shown that the polymorphism of the MIF gene at the -173 position was statistically correlated with CAD. [12] High levels of MIF protein are expressed in complications of type 2 diabetes mellitus (T2DM) such as myocardial injury, [13] CAD, [14] diabetic retinopathy, [15] obesity [16] and metabolic syndrome. [17] The MIF protein plays an indirect role in the development of T2DM by promoting the production of proinflammatory cytokines and adipocytokines that have a role in insulin receptor signaling which leads to the development of insulin resistance. [18] Several clinical studies have shown that serum MIF levels increase in T2DM patients. [19] In 2006, it has been suggested that before the onset of T2DM, blood MIF levels elevate. [20] Herder et al. [21] reported a significant increase in circulating levels of MIF, C-reactive protein (CRP) and interleukin-6 (IL-6) in T2DM patients compared to normoglycemic controls. The relationship between T2DM and MIF seems to be stronger than other proteins such as CRP and IL-6. [20] In a recent large cohort study, increased serum MIF levels were associated with a higher risk of T2DM in women than in men (HR 1.74). [21] Another factor that can explain the variability of MIF gene expression in populations is the detection of a series of different MIF promoter genotypes. [2, 22] The relationship between high plasma levels of MIF protein and longterm adverse outcomes in patients with stable CAD and T2DM has been reported in a prospective casecohort study performed in a Japanese population. [14] T2DM disease has been known for many years as an independent risk factor for atherosclerosis. However, in recent years, better understanding of the relationships between T2DM and the cardiovascular system, and in particular based on accumulated epidemiological evidence, atherosclerosis has been referred as a 'cardiovascular disease equivalent' in the risk assessment for T2DM. [23] Starting from this information, we aimed to investigate the contribution of MIF gene polymorphism to the coexistence of these two diseases in CAD and T2DM patients.
METHODS

Coronary artery disease and selection of controls
The patients who were detected as having significant CAD based on findings of coronary angiography (50-100% stenotic coronary lesion, n=139) performed according to the clinical findings and results of noninvasive ischemia tests, and as controls 259 individuals with normal coronary arteries or minimal atheroscle- Then, 259 individuals were included in the first subgroup according to their diabetes status as those with (n=112) and without T2DM (n=147). In our study, the second subgroup consisted of patients with both CAD and T2DM (n=74) and controls (n=80). The MIF gene -173G/C polymorphism was genotyped in all study groups and the MIF gene was statistically correlated with the generated groups. Before the study was started, approval was obtained from Istanbul University Istanbul Faculty of Medicine Clinical Research Ethics Committee and all patients whose samples were taken signed informed consent forms.
In this study, DNA bank formed from individuals who participated in the study between 2015 and 2016 was used for the investigation of the association with MIF gene polymorphism. Blood samples obtained from atherosclerotic CAD cases and controls were retrieved from T.C. Ufuk University Faculty of Medicine Department of Cardiology. The polymorphism of the MIF gene in 259 individuals (mean age; 62.9±10.7, 69.8% male) analyzed in the CAD DNA bank was genotyped in the -173G/C region. Angiographic prevalence and severity were determined by calculating the Gensini and SYNTAX scores of the individuals in the significant CAD group.
The Gensini score has become the gold standard over time, in grading the severity and prevalence of CAD. In this system, the severity of stenosis in the epicardial coronary artery (1: 1-25% stenosis, 2: 26-50% stenosis, 4: 51-75% stenosis, 8: 76-90% stenosis, 16: 91-99% stenosis and 32: total occlusion of the coronary artery) and the appropriate coefficient determined according to the anatomical location of the lesion were multiplied, and all values were summed up to obtain the Gensini score [24] The higher the Gensini score, the more serious and so widespread is CAD.
In patients with significant stenosis of the coronary artery (≥50% stenosis) the SYNTAX score was also calculated to evaluate the degree of complexity of CAD. The SYNTAX scoring system takes into account factors such as the location and distribution of the lesions, the length of the lesion, the presence of tortuosity, bifurcation or trifurcation lesion (if any). SYNTAX score of each 50% stenotic epicardial coronary artery with a diameter of >1.5 mm, was calculated by entering the values into the online SYNTAX calculator (version 2.1 www.syntaxscore.com).
Low (≤22), intermediate (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) and high (≥33). SYNTAX scores were defined as indicated. Patients with a SYNTAX score of ≥23 were defined as patients with moderate to severely complex CAD. [25] In addition to the coronary artery stenosis score, presence of family history, smoking, diabetes, and biochemical parameters such as, HbA1c and fasting blood glucose were also taken into consideration in the selection of individuals included in the study.
In the selection of the control group, in addition to the coronary stenosis of ≤30%, lack of diabetes, family history of CAD, cerebrovascular/peripheral artery disease, and the advanced age (≥55 years) were taken into consideration.
Biochemical analyzes
Blood samples were collected before coronary angiographic examination and stored in a freezer at -75°C until analysis. Samples with high lipid content, hemolysis, and those obtained from patients with jaundice were excluded from the study.
Biochemical parameters were analyzed in two central laboratories. Total cholesterol, fasting triglyceride, high density lipoprotein (HDL) -cholesterol and low density lipoprotein (LDL) -cholesterol concentrations were measured with UniCell DxC 800 (Beckman Coulter, USA) device Blood glucose levels were measured by spectrophotometric method using the Hexokinase / G-6-PDH reaction principle in Abbott c8000 Architect autoanalyser (Abbott Lifesciences, USA). HbA1c levels were analyzed using the High Performance Liquid Chromatography (HPLC) system, which is considered as the gold standard. The results were given as the ratio of glycosylated hemogobin to total hemoglobin in percentages (Hb%).
Genotyping with RT-PCR
In this study, a DNA bank containing blood samples of individuals who were diagnosed as CAD or specified as controls based on coronary angiography findings recorded between 2015 and 2016 were used for the investigation of the correlation between CAD, T2DM and MIF gene polymorphism. DNA was isolated from 10 mL of peripheral blood samples obtained from individuals included in the study and DNA bank con-tests. Significance was evaluated at p<0.05. All statistical calculations were performed using the Windows SPSS 21.0 (IBM, USA) program.
RESULTS
The polymorphism of MIF genes (mean age; 62.9±10.7, 69.8% male) studied in the promoter region was genotyped using hybridization probes in Light Cycler 480 (Fig. 1) .
In our study, clinical conditions and biochemical parameters are summarized in Table 2 according to T2DM in patients with and without significant CAD diagnosis.
MIF rs755622 genotype and allele frequencies
Genetic distributions of MIF rs755622 polymorphisms for GG, and GC + CC were found as 66.9% (n=93) and 33.1% (n=46), respectively. The frequency of C allele was found to be 18.7% in the significant CAD group. There was no statistically significant relationship between genotype and allele frequencies in significant CAD and control groups.
Similarly, the distributions of MIF rs755622 polymorphisms for GG, and GC+CC genotypes were found to be 65.8% (n=25) and 34.2% (n=13) in the CAD-DM group, respectively. The frequency of C allele was determined as 16.9% in the CAD-T2DM group. Any statistically significant relationship was not observed between genotype and allele frequencies in CAD-T2DM and control groups (p>0.05) (Fig. 2) .
taining samples of 259 individuals was established for the genotyping study. Genotyping was performed in DNA samples of total of 259 subjects in CAD-T2DM and control groups. Genotyping of DNA samples was performed on LightCycler ® 480 (Roche, Germany) using labeled hybridization probes by Real-Time PCR method. The hybridization probe-primer sequences used in the study are shown in Table 1 .
Statistical analysis
Continuous numerical (quantitative) values were expressed as mean ± standard deviation (SS) and categorical (nominal) values by percentage (%). Categorical variables in the study and control groups were compared with chi-square test and quantitative variables were compared with Student t-test and ANOVA. Univariate analysis or multiple regression analysis were used to determine the relationship between risk variables and cardiovascular diseases. The frequency of each allele was estimated, and the control of the studied population was determined by the HardyWeinberg equation for equilibrium and chi-square On the other hand, in the same subgroups, the MIF common genotype showed a protection against T2DM disease development in the control group compared to those without C allele carriers (p<0.05).
The Relationship between MIF rs755622 polymorphism and Gensini and SYNTAX scores
There was no statistically significant relationship between angiographic severity and prevalence of CAD (Gensini and SYNTAX scores) and genotypes of MIF rs755622 polymorphism (p>0.05). There was no statistically significant relationship between angiographic severity and prevalenceof the disease and genotypes of MIF rs755622 polymorphism in the T2DM group (Table 3) .
The relationship between MIF rs755622 polymorphism and cardiometabolic risk factors
In the CAD-T2DM group, C allele carriers of MIF rs755622 showed a statistically borderline relationship with HbA1c (GG: 0.83±0.093, GC+CC: 0.88±0.095, p=0.07). Regarding the biometric parameters and cardiovascular status of MIF genotypes in groups with and without T2DM independent of CAD group, no significant relationship was found with cardiovascular diseases.
In contrast, HbA1c (p=0.038) value was associated with C allele carriage in the T2DM group (Table  3) . When the univariant analysis was adjusted for gender and obesity, C allele carriage posed a risk for high HbA1c (Table 4 , p=0.036). No statistically significant correlation was found between these parameters and MIF rs755622 polymorphism in ANOVA and t-test analyzes which were specific for gender (p>0.05).
DISCUSSION
When groups with and without type 2 diabetes mellitus were compared C allele carriage was significantly associated with high HbA1c in the TD2M group. According to the results of our study, it is thought that MIF gene -173G/C polymorphism may increase the risk of CAD through T2DM in Turkish patients with significant CAD.
Recent studies have shown that MIF protein may play an important role in the development of T1DM and T2DM in glucose homeostasis. [26] [27] [28] MIF protein has a role in two different mechanisms of glucose metabolism; Firstly it exerts its effect on the response of insulin target cells and secondly, it directly induces insulin secretion from pancreatic beta cells. [19, 29] The circulating level of MIF protein, which plays a pathogenic role in insulin resistance, increases in patients with impaired glucose tolerance (IGT) and in patients with T2DM. [14] In addition, it has been shown that the increase in systemic MIF protein concentrations occurs before the onset of T2DM. This may be related to the higher incidence of atherosclerotic vascular disease in diabetic patients relative to non-diabetic patients. [20] Epidemiological and clinical trials have demonstrated the strong association between MIF protein and obesity, insulin resistance, and T2DM development. [30] In a previous study, it was found that serum MIF concentration increased from normoglycemia to impaired glucose intolerance and T2DM disease. [20] Herder et al. [20] reported an increase in circulating CRP, MIF and IL-6 levels in patients with IGT and T2DM compared to normoglycemic controls. associated with lower HDL-C and higher glucose, LDL-C, TG levels in the CAD group compared to the control group and a significant relationship was also found with the increased prevalence of hypertension and diabetes. [37] The strong positive correlation between MIF protein concentrations in patients with IGT and T2DM is independent of other immune mediators. In contrast to CRP and IL-6, there was a significant increase in MIF concentrations in the T2DM group compared to the IGT group, suggesting an increase in systemic MIF concentrations before the onset of T2DM. [28] In this study, MIF C allele carriage was associated with higher HbA1c levels in T2DM CAD group.
We have previously reported the presence of a correlation between cardiovascular risk factors such as obesity and T2DM and the MIF gene polymorphism in the adult Turkish population. [38] The tendency of carriage of the -173C allele to independently predict new-onset diabetes was limited to men. [38] In addition, a significant correlation was found between MIF serum level and diabetes and metabolic syndrome in Turkish Adult Heart Disease and Risk Factors (TARF) study. [39] In our study, we found that Gensini and SYNTAX scores in the T2DM patient group were statistically significant when compared to the group without T2DM. The relationship between T2DM disease and the scores associated with angiographic prevalence and severity of CAD is important for the investigation of the genetic predisposition of diabetes in CAD groups.
One of the main limitations of the study is that the MIF gene polymorphism could not be investigated in a larger number of patients. It should be investigated in greater number of groups to allow statistical analyzes according to gender and gender specific findings should be demonstrated. Another limitation of our study was that other SNPs of the MIF gene could not be included in the study. In addition, the inability to measure the level of MIF protein is another limitation of the study.
These results suggest that MIF gene variant may contribute to CAD risk through T2DM in Turkish population. Considering that T2DM disease is closely related to predisposition to CAD and angiographic severity, the genetic predisposition of the diabetic condition in the CAD group should be studied in detail.
In another study, serum levels of MIF protein were measured in prediabetic patients (HbA1c: 6.0-6.5) and a significant increase was observed compared to normal controls. [31] Similarly, high serum MIF levels were found in American Pima Indians, who had a high incidence of T2DM. [32] In a study by Makino et al., [14] MIF levels were measured in patients with stable CAD, including patients with IGT and T2DM. The results show that high MIF levels are independent risk factors for future coronary events in the CAD group with IGT/T2DM.
Gestational diabetes mellitus (GDM) is in many respects similar to T2DM disease, and in both cases the main pathophysiological mechanism leads to increased insulin resistance. The frequency of MIF rs755622 allele types was found to be statistically different between GDM and control groups. CC and CG genotypes were significantly associated with increased glucose levels and insulin resistance during OGTT in pregnant women with GDM. In conclusion, MIF gene rs755622 polymorphism was found to be associated with increased risk of GDM and insulin resistance in Han Chinese women. [33] MIF protein plays a critical role in the pathogenesis of CAD caused by atherosclerosis. It activates hemorrhagic microvessels in atherosclerosis. [34] During formation and progression of lesions, increased MIF gene expression was observed in vascular endothelial cells compared to normal arteries. [35] In a study, it was shown that there was a close relationship between CAD and the polymorphism in the MIF gene -173G/C position and the risk of CAD was found to be associated with an increased plasma MIF concentration in MIF -173C allele carriers. [36] When plasma MIF levels were compared in CAD and control groups, it was found that individuals with MIF -173C alleles in the CAD group had produced significantly higher levels of MIF protein. It has been suggested that individuals with the MIF -173C allele produce higher amounts of MIF protein. [36] In a population-based cohort study, the relationship between MIF genotypes, MIF serum levels and CAD risk was investigated. In women, the C-G-C-T haplotype was found to be significantly associated with increased CAD risk (HR 2.44, 95% CI 1. 30-4.59 ). This haplotype contains rs755622C allele, which was previously associated with other proinflammatory conditions. [11] In another study, this polymorphism was
Further study is required with larger sample groups to better identify the role of MIF gene polymorphism in the T2DM-CAD group. As a result of these studies, testing of these markers in the MIF gene in the followup of CAD development will contribute to the early diagnosis and development of gene-specific treatment strategies.
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